Improvements to our Neuro Exploratory panel

In response to customer feedback and as part of Olink’s commitment to improve and develop our offering, a number of changes have been made to our Neuro Exploratory panel.  As data from this panel has accumulated, it became apparent that these two of the original assays would fit better in a pa...

Breakthrough publication on ovarian cancer

June 24, 2019. A breakthrough new publication from Enroth et al describes how broad screening of more than 590 proteins using Olink panels identified a high-accuracy 11-protein signature for ovarian cancer that could be verified in replication cohorts. These proteins were then devel...

Improvements to our Immuno-Oncology panel

In response to customer feedback and as part of Olink’s commitment to improve and develop our offering, a number of changes have been made to our Immuno-Oncology panel. Significant improvements in detectabilty have been made for two key existing assays, and four new assays that are highly rele...

A successful symposium in Utrecht

On Thursday May 2, 2019  UMC Utrecht and Olink held a symposium, “A proteomics perspective on Precision Medicine”. Around 60 scientists attended the event, which featured a series of outstanding presentations and an engaged and knowledgeable audience. The five customer tal...

Interview with Olink’s CEO in Business Trends

Business Trends magazine recently interviewed Olink Proteomics CEO, Jon Heimer and have published an article in which he outlines the company’s commitment to support the development of precision medicine by providing enabling solutions for protein biomarker discovery, development and implement...

Inflammation panel update

April 3, 2019. Olink® INFLAMMATION is the most widely used and most frequently cited Olink panel. After listening to feedback from our customers, we have made significant improvements to two key assays within this panel of 92 inflammation-related proteins. Our new assays for Tumor Necrosis Factor (T...

Summa Equity acquires Olink Proteomics

TUE, MAR 12, 2019 08:30 CET Summa Equity acquires Olink Proteomics, a Swedish life science company that has developed a unique technology for human biomarker discovery, targeting the global biopharma and academic research and discovery markets. Olink’s purpose is to enable precision...

Olink into Asia

A new member of the Olink family joins us in Singapore! We are delighted to introduce Dr. Wen Jing Sim, who will represent Olink Proteomics as our first Business Development Manager in Asia. Wen Jing will be based in Singapore, and support new and existing customers based in a broad region includin...

Available now- a new protein biomarker panel for oncology

December 13, 2018. A new 92-plex protein panel containing a combination of  established and exploratory markers focused on oncology is now available for immediate shipment as kits, or via our Analysis Service. This panel provides a perfect complement to our existing panel, Olink® O...

Coming soon – a new protein biomarker panel for oncology

A new 92-plex protein panel containing a combination of  established and exploratory markers focused on oncology will be available in December for shipment as kits, or via our Analysis Service. This panel will provide a perfect complement to our existing panel, Olink® ONCOLOGY II, enabling oncologi...